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This is the ﬁrst report of alveolar hemorrhage due to erlotinib. This patient had received four courses of
carboplatin and paclitaxel as ﬁrst line chemotherapy. Six months later,the level of serum CEA was
increased. As cancer cells detected in right bloody pleural effusion indicated an adenocarcinoma showing
in frame deletion in exon 19 (E746-A750 del) of epidermal growth factor receptor (EGFR) mutation,
geﬁtinib was administered. The level of serum CEAwas decreased for three months. However, the level of
serum CEA increased again. Therefore, she was hospitalized to begin erlotinib treatment as third line
chemotherapy. She did not respond to erlotinib, but severe alveolar hemorrhage did occur and was
suspected to have been a resul of erlotinib administration We should consider that there may be a risk of
alveolar hemorrhage due to erlotinib administration in non-small-cell lung cancer resistant to geﬁtinib.
 2009 Elsevier Ltd. All rights reserved.1. Case report
A 75-year-old female was admitted to our hospital for third
line chemotherapy with erlotinib on 15 January, 2008. She had
initially been referred by a local doctor for massive right pleural
effusion on 2 February, 2007 and diagnosed as having lung cancer
T4N1M0 (stage IIIB) (Fig. 1(a)). She had received four courses of
carboplatin and paclitaxel as ﬁrst line chemotherapy. Cancer cells
detected in right bloody pleural effusion indicated an adenocar-
cinoma showing in-frame deletion in exon 19 (E746-A750 del) of
epidermal growth factor receptor (EGFR) mutation. Therefore,
geﬁtinib was administered from 12 June. The level of serum CEA
was decreased from 255.0 ng/ml to 17.5 ng/ml on 10 September.
Chest radiograph showed a right hilar mass and moderate amount
of pleural effusion (Fig. 1(b)). However, the level of serum CEA
increased again to 107.3 ng/ml on 7 January, 2008. Therefore, she
was hospitalized to begin erlotinib treatment as third line
chemotherapy. Eight days after administration of erlotinib,
hemoptysis of 20 ml was noted. Hemoglobin and arterial partial
oxygen pressure before admission did not change after adminis-
tration, and the patient recovered by the administration of
carbazochrome and tranexamic acid as hemostatics. We strictly
observed her clinical course, judging that the bleeding had been
due to the anticancer effect of erlotinib, although a small amountof bloody sputum persisted. On 18 March, she demonstrated
massive hemoptysis of more than 50 ml with fever of 38 C. On
chest radiograph, bilateral diffuse inﬁltration was newly detected
(Fig. 1(c)). Hemoglobin decreased remarkably from 7.4 g/dl to
5.6 g/ml over two days. Bleeding time was normal and the platelet
count was 29.7104/ml. CRP and LDH did not change from those
at admission. The PR3-ANCA and MPO-ANCA were within normal
ranges. Urinalysis did not show either macro or microhematuria.
On bronchoscopy, there was massive bleeding from the bilateral
bronchial tree. Erlotinib was stopped considering that erlotinib
might have induced alveolar hemorrhage. Then 800 ml of red
blood cells was transfused. Methylprednisolone of 500 mg was
administered for three days and then 10 mg of prednisolone was
administered. After three days, the patient improved and she
discharged on 1 April, 2008.
2. Discussion
Non-small-cell lung cancer (NSCLC) is the leading cause of
cancer-related mortality worldwide. The epidermal growth factor
receptor (EGFR) mediates cancer cell growth, proliferation, inva-
sion, and metastasis, and inhibits apoptosis.1 When ligands bind to
the receptor, the molecule is phosphorylated by constitutive tyro-
sine kinases, causing activation of the downstream pathways.2 The
EGFR inhibitors geﬁtinib and erlotinib have shown promising
results in the treatment of NSCLC.3
The double-blind, randomized phase III Iressa Survival Evalua-
tion in Lung (ISEL) cancer trial compared geﬁtinib 250 mg plus best
Fig. 1. (a) Chest radiograph on 2 February 2007. (b) Chest radiograph on 10 September 2007 showing improvement of right pleural effusion. (c) Chest radiograph on the second
admission newly showed bilateral inﬁltration.
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icant overall survival beneﬁt for geﬁtinib in either the entire trial
population or in the subgroup of patients with adenocarcinoma. A
survival beneﬁt in favor of geﬁtinib was observed among 22% of
patients who had never smoked and among 20% of those of Asian
origin.4 In 2004, two independent groups reported an association
between somatic EGFR mutations and a dramatic clinical response
to geﬁtinib.5,6 The mutations consisted of small, in-frame deletions
or substitutions clustered around the adenosine triphosphate-
binding site on exons 18, 19, and 21 of the EGFR gene, and
approximately 90% of patients with EGFRmutations have one of the
two major mutations.7 One is a 15-base pair nucleotide in-frame
deletion (E746-A750 del) in exon 19 and the other is a point
mutation involving the replacement of leucine with arginine at
codon 858 (L858R) in exon 21.8 In this case, the patient was
a Japanese woman who had never smoked and the cancer cells
from right pleural effusion disclosed an adenocarcinoma with an
in-frame deletion in exon 19 (E746-A750 del) of EGFR. Therefore,
we expected she would respond to administration of geﬁtinib and
in fact the level of serum CEA decreased for 7 months. When the
level of serum CEA increased again, we chose erlotinib based on
reports describing two cases demonstrating a successful response
to erlotinib after failing of geﬁtinib.9,10 Kobayashi et al. reported
a patient with EGFR-mutant, geﬁtinib-responsive, advanced NSCLC
who had a relapse after two years of complete remission during
treatment with geﬁtinib.11 The DNA sequence of the EGFR gene in
the tumor biopsy specimen at relapse demonstrated the presence
of a second point mutation, resulting in a threonine-to-methionine
amino acid change at position 790 of EGFR. Our patient did not
respond to erlotinib, but alveolar hemorrhage did occur and was
suspected to have been the result of erlotinib administration. With
geﬁtinib, severe alveolar hemorrhage was reported in the Japanese
literature.12 Although the mechanism of alveolar hemorrhage
following erlotinib administrationwas not determined, some reports
in geﬁtinib have suggested some mechanisms underlying alveolar
hemorrhage. Hirata et al. reported that geﬁtinib inhibited angiogen-
esis induced by EGF.13 Apoptosis in human cancer cells induced by
treatment with EGFR-TKI, but venous endothelial cells also demon-
strated apoptosis.14,15 Erlotinib, although there were no previous
reports of alveolar hemorrhage, bilateral subdural hemorrhage with
exacerbation of radiodermatitis after whole brain irradiation
combined with erlotinib was reported.16 In that report, geﬁtinib was
replaced with erlotinib on the ﬁfth day after whole brain irradiation.
The standarddoses of 250 mggeﬁtinib and150 mgerlotinibwere not
biologically equivalent. Erlotinibwas administered at themaximum-tolerateddose,whereas geﬁtinibwas administratedat approximately
one-third of its maximum-tolerated dose.17 Furthermore, erlotinib
may have higher-afﬁnity binding to the EGFR kinase domain than
geﬁtinib has.18 Therefore, erlotinib has an effectively toxic dose.
We should consider that there might be a risk of alveolar
hemorrhage due to erlotinib administration in non-small-cell lung
cancer resistant to geﬁtinib.
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